These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33577421)

  • 21. An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice.
    Honda-Okubo Y; Sakala IG; André G; Tarbet EB; Hurst BL; Petrovsky N
    Vaccine; 2023 Aug; 41(38):5592-5602. PubMed ID: 37532610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
    Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
    Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Broadly Protective CD8
    Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
    J Virol; 2021 May; 95(12):. PubMed ID: 33827939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.
    Wodal W; Schwendinger MG; Savidis-Dacho H; Crowe BA; Hohenadl C; Fritz R; Brühl P; Portsmouth D; Karner-Pichl A; Balta D; Grillberger L; Kistner O; Barrett PN; Howard MK
    PLoS One; 2015; 10(2):e0113963. PubMed ID: 25719901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice.
    Yam KK; Gupta J; Allen EK; Burt KR; Beaulieu É; Mallett CP; Burt DS; Ward BJ
    Vaccine; 2016 Mar; 34(12):1444-51. PubMed ID: 26873056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivated Antigen of the H7N9 Influenza Virus Protects Mice from Its Lethal Infection.
    Seo SH; Kim HS
    Viral Immunol; 2016 May; 29(4):235-43. PubMed ID: 26910526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial.
    El Sahly HM; Yildirim I; Frey SE; Winokur P; Jackson LA; Bernstein DI; Creech CB; Chen WH; Rupp RE; Whitaker JA; Phadke V; Hoft DF; Ince D; Brady RC; Edwards KM; Ortiz JR; Berman MA; Weiss J; Wegel A;
    J Infect Dis; 2024 Feb; 229(2):327-340. PubMed ID: 37466221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.
    Clark TW; Pareek M; Hoschler K; Dillon H; Nicholson KG; Groth N; Stephenson I
    N Engl J Med; 2009 Dec; 361(25):2424-35. PubMed ID: 19745215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced humoural and cellular immune responses to influenza H7N9 antigen HA1-2 fused with flagellin in chickens.
    Song L; Xiong D; Hu M; Kang X; Pan Z; Jiao X
    BMC Vet Res; 2017 Jun; 13(1):190. PubMed ID: 28637471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A broadly neutralizing human monoclonal antibody against the hemagglutinin of avian influenza virus H7N9.
    Li J; Zhang L; Bao L; Wang Y; Qiu L; Hu J; Tang R; Yu H; Shan J; Li Y; Qin C; Zhu F
    Chin Med J (Engl); 2022 Apr; 135(7):799-805. PubMed ID: 35671181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.
    Madan A; Ferguson M; Sheldon E; Segall N; Chu L; Toma A; Rheault P; Friel D; Soni J; Li P; Innis BL; Schuind A
    Vaccine; 2017 Mar; 35(10):1431-1439. PubMed ID: 28187952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
    Madan A; Segall N; Ferguson M; Frenette L; Kroll R; Friel D; Soni J; Li P; Innis BL; Schuind A
    J Infect Dis; 2016 Dec; 214(11):1717-1727. PubMed ID: 27609809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine.
    Ou H; Yao W; Wu N; Wang FX; Weng T; Han C; Lu X; Yu D; Wu H; Cheng L; Chen H; Yao H; Li L
    Oncotarget; 2016 Dec; 7(49):81012-81025. PubMed ID: 27768591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of avian influenza virus isolated from ducks as a potential live vaccine candidate against novel H7N9 viruses.
    Jiang WM; Wang SC; Liu HL; Yu JM; Du X; Hou GY; Li JP; Liu S; Wang KC; Zhuang QY; Liu XM; Chen JM
    Vaccine; 2014 Nov; 32(48):6433-9. PubMed ID: 25285880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single immunization with MF59-adjuvanted inactivated whole-virion H7N9 influenza vaccine provides early protection against H7N9 virus challenge in mice.
    Chang H; Duan J; Zhou P; Su L; Zheng D; Zhang F; Fang F; Li X; Chen Z
    Microbes Infect; 2017 Dec; 19(12):616-625. PubMed ID: 28899814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes.
    Lee AC; Zhu H; Zhang AJ; Li C; Wang P; Li C; Chen H; Hung IF; To KK; Yuen KY
    Clin Vaccine Immunol; 2015 Dec; 22(12):1235-43. PubMed ID: 26446420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.